The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide.
Open accessAbstract
The beta-amyloid peptide, the hallmark of Alzheimer disease, forms fibrillar toxic aggregates in brain tissue that can be dissolved only by strong denaturing agents. To study beta-amyloid formation and its inhibition, we prepared immune complexes with two monoclonal antibodies (mAbs), AMY-33 and 6F/3D, raised against beta-amyloid fragments spanning amino acid residues 1-28 and 8-17 of the beta-amyloid peptide chain, respectively. In vitro aggregation of beta-amyloid peptide was induced by incubation for 3 h at 37 degrees C and monitored by ELISA, negative staining electron microscopy, and fluorimetric studies. We found that the mAs prevent the aggregation of beta-amyloid peptide and that the inhibitory effect appears to be related to the localization of the antibody-binding sites and the nature of the aggregating agents. Preparation of mAbs against "aggregating epitopes," defined as sequences related to the sites where protein aggregation is initiated, may lead to the understanding and prevention of protein aggregation. The results of this study may provide a foundation for using mAbs in vivo to prevent the beta-amyloid peptide aggregation that is associated with Alzheimer disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Levine, H. (1993) · Protein Science · doi:10.1002/pro.5560020312 · Cited by 2,264
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447
Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state
Pike, C., Burdick, D., Walencewicz, A., Glabe, C., & Cotman, C. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-04-01676.1993 · Cited by 1,417
Ellis, R. J., & van der Vies, S. M. (1991) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.60.070191.001541 · Cited by 1,120
Neurobiology of Zinc and Zinc-Containing Neurons
Frederickson, C. J. (1989) · International Review of Neurobiology · doi:10.1016/s0074-7742(08)60279-2 · Cited by 1,075
Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs.
Burdick, D., Soreghan, B., Kwon, M., Kosmoski, J., Knauer, M., Henschen, A., Yates, J., Cotman, C., & Glabe, C. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48529-8 · Cited by 1,014
In vitro aging of ß-amyloid protein causes peptide aggregation and neurotoxicity
Pike, C. J., Walencewicz, A. J., Glabe, C. G., & Cotman, C. W. (1991) · Brain Research · doi:10.1016/0006-8993(91)91553-d · Cited by 828
Intramuscular desferrioxamine in patients with Alzheimer's disease
MCLACHLAN, D. (1991) · The Lancet · doi:10.1016/0140-6736(91)92978-b · Cited by 764
Mantyh, P. W., Ghilardi, J. R., Rogers, S., DeMaster, E., Allen, C. J., Stimson, E. R., & Maggio, J. E. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03639.x · Cited by 465
Transthyretin sequesters amyloid beta protein and prevents amyloid formation.
Schwarzman, A. L., Gregori, L., Vitek, M. P., Lyubski, S., Strittmatter, W. J., Enghilde, J. J., Bhasin, R., Silverman, J., Weisgraber, K. H., & Coyle, P. K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8368 · Cited by 413
Snyder, S. W., Ladror, U. S., Wade, W. S., Wang, G. T., Barrett, L. W., Matayoshi, E. D., Huffaker, H. J., Krafft, G. A., & Holzman, T. F. (1994) · Biophysical Journal · doi:10.1016/s0006-3495(94)80591-0 · Cited by 381
Snow, A. D., Sekiguchi, R., Nochlin, D., Fraser, P., Kimata, K., Mizutani, A., Arai, M., Schreier, W. A., & Morgan, D. G. (1994) · Neuron · doi:10.1016/0896-6273(94)90165-1 · Cited by 299
Aggregation-related toxicity of synthetic β-amyloid protein in hippocampal cultures
Pike, C. J., Walencewicz, A. J., Glabe, C. G., & Cotman, C. W. (1991) · European Journal of Pharmacology: Molecular Pharmacology · doi:10.1016/0922-4106(91)90014-9 · Cited by 276
Marasco, W. A., Haseltine, W. A., & Chen, S. Y. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.16.7889 · Cited by 268
Fraser, P. E., Nguyen, J. T., Chin, D. T., & Kirschner, D. A. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08470.x · Cited by 212
Apolipoprotein E: Binding to Soluble Alzheimer′s β-Amyloid
Wisniewski, T., Golabek, A., Matsubara, E., Ghiso, J., & Frangione, B. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1423 · Cited by 212
Koo, E. H., Park, L., & Selkoe, D. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.10.4748 · Cited by 181
Solution Structure of Residues 1-28 of the Amyloid .beta.-Peptide
Talafous, J., Marcinowski, K. J., Klopman, G., & Zagorski, M. G. (1994) · Biochemistry · doi:10.1021/bi00191a006 · Cited by 178
Rifampicin Prevents the Aggregation and Neurotoxicity of Amyloid β Protein in Vitro
Tomiyama, T., Asano, S., Suwa, Y., Morita, T., Kataoka, K., Mori, H., & Endo, N. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2428 · Cited by 158
Antibody Assisted Protein Refolding
Carlson, J. D., & Yarmush, M. L. (1992) · Nature Biotechnology · doi:10.1038/nbt0192-86 · Cited by 52
Biochemistry of Alzheimer's disease amyloid plaques
Fraser, P. E., Lévesque, L., & McLachlan, D. R. C. (1993) · Clinical Biochemistry · doi:10.1016/0009-9120(93)90110-r · Cited by 42
Chaperone‐like effect of monoclonal antibodies on refolding of heat‐denatured carboxypeptidase A
Solomon, B., & Schwartz, F. (1995) · Journal of Molecular Recognition · doi:10.1002/jmr.300080113 · Cited by 32
Self-citation
Cited by
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Harper, J. D., & Lansbury, P. T. (1997) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.66.1.385 · Cited by 1,652
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
The Amyloid Beta Peptide: A Chemist’s Perspective. Role in Alzheimer’s and Fibrillization
Hamley, I. W. (2012) · Chemical Reviews · doi:10.1021/cr3000994 · Cited by 882
Alzheimer's Disease: Molecular Understanding Predicts Amyloid-Based Therapeutics
Selkoe, D. J., & Schenk, D. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140248 · Cited by 818
Metadata
- Authors
- Solomon, B., Koppel, R., Hanan, E., & Katzav, T.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1996-01-09
- Volume
- 93
- Issue
- 1
- Pages
- 452-455
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1998227221
- Cited by
- 316
- References
- 26
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.